An Expert Working Group (EWG) of the Commission on Human Medicines (CHM), advising the Medicines and Healthcare Products Regulatory Agency (MHRA), has concluded a detailed review into how the potential risks associated with 28 antidepressant medicines are communicated to patients within the Patient Information Leaflet (PIL).

The review was launched after concerns were raised by families and patients that current safety warnings in the PILs for these medicines did not clearly explain certain side effects – specifically suicidal behaviours, and sexual dysfunction that may continue after the treatment is stopped.

Over the past 18 months, the EWG has heard directly from families, patients, and mental health support organisations. The group considered the real-world experiences of those affec

See Full Page